# Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

> **NCT05468242** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 116 (estimated)

## Conditions studied

- Stage III Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Neoadjuvant chemo-immunotherapy
- **DRUG:** Bevacizumab
- **RADIATION:** Radiotherapy
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05468242
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468242, "Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05468242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*